These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29402301)

  • 1. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
    Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
    J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
    Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor.
    Holdbrooks AT; Britain CM; Bellis SL
    J Biol Chem; 2018 Feb; 293(5):1610-1622. PubMed ID: 29233887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ST6Gal-I-mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion.
    Rao TC; Beggs RR; Ankenbauer KE; Hwang J; Ma VP; Salaita K; Bellis SL; Mattheyses AL
    J Biol Chem; 2022 Apr; 298(4):101726. PubMed ID: 35157848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells.
    Britain CM; Bhalerao N; Silva AD; Chakraborty A; Buchsbaum DJ; Crowley MR; Crossman DK; Edwards YJK; Bellis SL
    J Biol Chem; 2021; 296():100034. PubMed ID: 33148698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
    Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
    J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics.
    Ankenbauer KE; Rao TC; Mattheyses AL; Bellis SL
    J Biol Chem; 2023 Oct; 299(10):105217. PubMed ID: 37660914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
    Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
    J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.
    Swindall AF; Bellis SL
    J Biol Chem; 2011 Jul; 286(26):22982-90. PubMed ID: 21550977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
    Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
    J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
    Frasca F; Vella V; Nicolosi ML; Messina RL; Gianì F; Lotta S; Vigneri P; Regalbuto C; Vigneri R
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2502-12. PubMed ID: 23559083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
    Zhu S; Belkhiri A; El-Rifai W
    Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.
    Britain CM; Dorsett KA; Bellis SL
    J Biol Chem; 2017 Mar; 292(11):4663-4673. PubMed ID: 28154177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.
    Jones RB; Dorsett KA; Hjelmeland AB; Bellis SL
    J Biol Chem; 2018 Apr; 293(15):5659-5667. PubMed ID: 29475939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
    Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
    Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
    Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
    Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
    Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
    Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance.
    Ou L; He X; Liu N; Song Y; Li J; Gao L; Huang X; Deng Z; Wang X; Lin S
    Mol Med Rep; 2020 Mar; 21(3):1449-1460. PubMed ID: 32016470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.